 BAUDETTE, Minn.--BUSINESS WIRE--ANI Pharmaceuticals, Inc. ANI or the Company Nasdaq: ANIP today announced that ANIs Board of Directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ANIs common stock to Ori Gutwerg, ANIs Senior Vice President, Generics, and an aggregate of 33,758 shares to Christopher Mutz, ANIs Chief Commercial Officer Head of Rare Disease, effective February 15, 2021. The stock options were granted as inducement 